Betaxolol

Betaxolol
Systematic (IUPAC) name
(RS)-1-{4-[2-(cyclopropylmethoxy)ethyl]-
phenoxy}-3-(isopropylamino)propan-2-ol
Clinical data
Trade names Kerlone
AHFS/Drugs.com monograph
MedlinePlus a609023
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
oral, ocular
Legal status
  • (Prescription only)
Pharmacokinetic data
Bioavailability 89%
Metabolism Hepatic
Biological half-life 14–22 hours
Excretion Renal (20%)
Identifiers
CAS Number 63659-18-7 YesY
ATC code C07AB05 (WHO) S01ED02
PubChem CID 2369
IUPHAR/BPS 549
DrugBank DB00195 YesY
ChemSpider 2279 YesY
UNII O0ZR1R6RZ2 YesY
KEGG D07526 YesY
ChEBI CHEBI:3082 YesY
ChEMBL CHEMBL423 YesY
Chemical data
Formula C18H29NO3
Molar mass 307.428 g/mol
Chirality Racemic mixture
  (verify)

Betaxolol (trade names Betoptic, Betoptic S, Lokren, Kerlone) is a selective beta1 receptor blocker used in the treatment of hypertension and glaucoma.[1] Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta2 receptors) as timolol may. Betaxolol also shows greater affininty for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

Betaxolol was approved by the U.S. Food and Drug Administration (FDA) for ocular use as a 0.5% solution (Betoptic) in 1985 and as a 0.25% solution (Betoptic S) in 1989.

Clinical uses

Dosage

Contraindications

See also

References

  1. Buckley, MM; Goa, KL; Clissold, SP (July 1990). "Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.". Drugs 40 (1): 75–90. doi:10.2165/00003495-199040010-00005. PMID 2202584.

External links

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.